Add Company
Join Now

Cellerant Therapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cellerant Therapeutics's estimated annual revenue is currently $2.8M per year.(i)
  • Cellerant Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Cellerant Therapeutics has 18 Employees.(i)
  • Cellerant Therapeutics grew their employee count by 200% last year.

Cellerant Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Cellerant Therapeutics?

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L is a universal cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. In a randomized, controlled Phase 2 clinical trial in AML patients, romyelocel-L reduced infections and days in hospital. Cellerant is developing two novel antibody drug-conjugate (ADC) products: CLT030 to treat AML by selectively targeting and killing leukemic stem and blast cells, and CSC012-ADC for hematologic malignancies and solid tumor indications.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$2.8M

Revenue (est)

200%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.8M1813%N/A
#2
$2.8M1813%N/A
#3
$1.7M190%N/A
#4
$1.6M190%N/A
#5
$3.8M19-14%N/A